HaemoneticsNYSE: HAE

Haemonetics (HAE) expands its VASCADE portfolio with the limited market release of VASCADE MVP XL vascular closure device.

BOSTON , June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a limited market release of its new VASCADE MVP® XL mid-bore venous closure device. The VASCADE MVP XL system expands Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors looking for stocks in the Medical - Products sector might want to consider either Haemonetics (HAE) or Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?

Haemonetics (HAE) is gaining from the newly completed limited market release of the new Express Plus technology with more than 60,000 real-world collections.

With earnings estimate revisions on the rise for these top medical stocks, they certainly shouldn't be overlooked given their blazing historical performances.

HAE made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 6, 2024.

HWM, LGND, MATX, SMFKY and HAE have been added to the Zacks Rank #1 (Strong Buy) List on June 6, 2024.

Listening to the Zacks Rank can consistently result in market-beating gains, as positive earnings estimate revisions provide the fuel needed for shares to move higher.